(+/-) 5-Ethyl-4,5-dihydro-5-hydroxy-7-trimethylsilyl-9-methoxyoxepino[3,4-c]pyridin-3(1H)-one | 300582-85-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (+/-) 5-Ethyl-4,5-dihydro-5-hydroxy-7-trimethylsilyl-9-methoxyoxepino[3,4-c]pyridin-3(1H)-one
• 英文别名: 5-Ethyl-4,5-dihydro-5-hydroxy-7-trimethylsilyl-9-methoxyoxepino[3,4-c]pyridin-3(1H)-one；5-ethyl-5-hydroxy-9-methoxy-7-trimethylsilyl-1,4-dihydrooxepino[3,4-c]pyridin-3-one
• CAS: 300582-85-8
• 化学式: C₁₅H₂₃NO₄Si
• 分子量: 309.437
• InChiKey: SGBQLXLZFSQVRW-UHFFFAOYSA-N

物化性质

• 沸点：
  424.3±45.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.68
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  68.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (+/-) 5-Ethyl-4,5-dihydro-5-hydroxy-7-trimethylsilyl-9-methoxyoxepino[3,4-c]pyridin-3(1H)-one 在 碘代三甲硅烷 、 一氯化碘 、 sodium hydride 、 lithium bromide 作用下， 以 乙二醇二甲醚 、 N,N-二甲基甲酰胺 为溶剂， 生成 (+/-) 5-Ethyl-1,4,5-trihydro-5-hydroxy-7-iodo-8-(3-tert-butyldimethylsilyl-2-propynyl)-oxepino[3,4-c]pyridine-3,9-dione
  参考文献：
  名称：

  Novel A,B,E-Ring-Modified Camptothecins Displaying High Lipophilicity and Markedly Improved Human Blood Stabilities

  摘要：

  DOI：

  10.1021/jm9902279
• 作为产物：
  描述：

  4-Ethyl-8-methoxy-6-trimethylsilanyl-1H-pyrano[3,4-c]pyridine 在 lead(IV) acetate 、 四氧化锇 、 三氟乙酸 作用下， 生成 (+/-) 5-Ethyl-4,5-dihydro-5-hydroxy-7-trimethylsilyl-9-methoxyoxepino[3,4-c]pyridin-3(1H)-one
  参考文献：
  名称：

  Novel A,B,E-Ring-Modified Camptothecins Displaying High Lipophilicity and Markedly Improved Human Blood Stabilities

  摘要：

  DOI：

  10.1021/jm9902279

文献信息

• Camptothecin analogs and methods of preparation thereof
  申请人：——

  公开号：US20010003779A1

  公开（公告）日：2001-06-14

  A method of synthesizing a compound having the formula 1 via a cascade radical 4+1 annulation includes the step wherein the precursor 2 is reacted with an arylisonitrile having the formula 3 wherein X is a radical precursor such as Cl, Br or I. R 6 is preferably —Si(R 8 R 9 R 10 ) or —(R 7 )Si(R 8 R 9 R 10 ), wherein R 7 is an alkylene group, an alkenylene group, or an alkynylene group; and R 8 , R 9 and R 10 are independently a C 1-10 alkyl group, a C 2-10 alkenyl group, a C 2-10 alkynyl group, an aryl group or a —(CH 2 ) N R 11 group, wherein N is an integer within the range of 1 through 10 and R 11 is a hydroxy group, alkoxy group, an amino group, an alkylamino group, a dialkylamino group, a halogen atom, a cyano group, —SR c or a nitro group. R 1 -R 4 can be broadly substituted. R 5 is preferably a C 1-10 alkyl group, an alkenyl group, an alkynyl group, or a benzyl group. R 13 is preferably H, F or —CH 3 . R 16 is R 16 is —C(O)R f or H. The E-ring (the lactone ring) may be opened.

  通过级联自由基4+1环化合成具有公式1的化合物的方法包括步骤，其中前体2与具有公式3的芳基异腈反应，其中X是类似Cl、Br或I的基团前体。R6优选为—Si(R8R9R10)或—(R7)Si(R8R9R10)，其中R7是烷基、烯基或炔基；R8、R9和R10独立地是C1-10烷基、C2-10烯基、C2-10炔基、芳基或—(CH2)NR11基团，其中N在1到10范围内，R11是羟基、烷氧基、氨基、烷基氨基、二烷基氨基、卤素原子、氰基、—SRc或硝基。R1-R4可以广泛取代。R5优选为C1-10烷基、烯基、炔基或苄基。R13优选为H、F或—CH3。R16为C(O)R对于H。E环（内酯环）可以打开。
• Intermediates in the preparation of homocamptothecin analogs
  申请人：University of Pittsburgh - of the Commonwealth System of Higher Education

  公开号：US07538220B2

  公开（公告）日：2009-05-26

  A compound having the formula in racemic form, enantiomerically enriched form or enantiomerically pure form; wherein X is a radical precursor; R5 is a C1-10 alkyl group, an alkenyl group, an alkynyl group, or a benzyl group; R6 is an alkyl group, —Si(R8R9R10) or —(R7)Si(R8R9R10), wherein R7 is an alkylene group, an alkenylene group, or an alkynylene group; and R8, R9 and R10 are independently a C1-10 alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group, an aryl group or a —(CH2)NR11 group, wherein N is an integer within the range of 1 through 10 and R11 is a hydroxy group, an alkoxy group, an amino group, an alkylamino group, a dialkylamino group, a halogen atom, a cyano group, —SRc or a nitro group; and R13 is H, F or —CH3.

  该化合物具有以下公式，包括其外消旋形式，对映富集形式或对映纯形式;其中X是基团前体; R5是C1-10烷基，烯基，炔基或苄基; R6是烷基，-Si（R8R9R10）或-(R7)Si（R8R9R10），其中R7是烷基，烯基或炔基; R8、R9和R10独立地是C1-10烷基，C2-10烯基，C2-10炔基，芳基或-(CH2)NR11基，其中N在1到10的范围内，R11是羟基，烷氧基，氨基，烷基氨基，二烷基氨基，卤素原子，氰基，-SRc或硝基; R13是H，F或-CH3。
• CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF
  申请人：CURRAN DENNIS P.

  公开号：US20120136153A1

  公开（公告）日：2012-05-31

  A compound having the formula in racemic form, enantiomerically enriched form or enantiomerically pure form, and pharmaceutically acceptable salts thereof.

  一种具有如下式的化合物，包括其外消旋体形式，对映体富集形式或对映体纯形式，以及其药学上可接受的盐。